{
  "outcomes_metadata": {
    "timestamp": "2025-09-29T13:21:06.198535",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 143,
    "source_countries": [
      "AT",
      "BE",
      "CZ",
      "DE",
      "DK",
      "EN",
      "ES",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "all-cause mortality",
        "survival",
        "median survival (by HCC stage)",
        "long-term survival",
        "improved survival",
        "mortality not related to hepatocellular carcinoma",
        "perioperative mortality",
        "treatment-related mortality",
        "deaths"
      ],
      "response_measures": [
        "objective response rate (ORR)",
        "objective response rate (ORR; mRECIST)",
        "objective response rate (ORR; RECIST 1.1)",
        "tumor response rate",
        "tumour response (RECIST criteria)",
        "tumour response (mRECIST criteria)",
        "response rates (RECIST criteria)",
        "response rates (mRECIST)",
        "response rates (RECIS systems)",
        "partial response (PR)",
        "complete response (CR)",
        "complete remission",
        "minor response (reduction of tumour size by 25 to 50%)",
        "stable disease (SD)",
        "stable disease for at least 16 weeks",
        "disease control rate (DCR)",
        "disease control rate (DCR; mRECIST)",
        "clinical benefit rate (CBR)",
        "disease control",
        "tumor reduction",
        "tumour recurrence",
        "recurrence-free survival",
        "recurrence risk",
        "recurrence rate",
        "risk of recurrence",
        "early detection of recurrences",
        "bridging therapy success",
        "effectiveness of ablation (magnetic resonance imaging)",
        "effectiveness of ablation (multiphase computed tomography)",
        "effectiveness of ablation (not ultrasonography)",
        "completeness of ablation (multiphase computed tomography with contrast)",
        "completeness of ablation (magnetic resonance imaging with contrast)"
      ],
      "progression_measures": [
        "progression-free survival (PFS)",
        "progression-free survival (PFS; RECIST 1.1)",
        "progression-free survival (PFS; mRECIST)",
        "progression-free survival (modified RECIST criteria)",
        "progression-free survival (RECIST 1.1)",
        "progression-free survival",
        "time to progression (TTP)",
        "time to progression",
        "time to tumour progression",
        "time to progression of the tumor",
        "time to radiological disease progression",
        "time to symptomatic progression (TTSP)",
        "time to symptomatic disease progression (FHSI-8 questionnaire)",
        "time to symptom progression",
        "time to response",
        "duration of response (DoR)",
        "duration of response (DoR; time from partial or complete response to disease progression or exit)",
        "disease progression",
        "tumour progression",
        "progression grading",
        "reassessment in progression classification",
        "local control"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (general)",
        "adverse reactions (general)",
        "adverse events (graded according to National Cancer Institute)",
        "adverse events (Grade ≥ 3)",
        "adverse events of chemotherapeutic agents",
        "undesirable effects (general)",
        "complications",
        "post-treatment complications",
        "serious adverse events",
        "serious adverse reactions (grade 3/4)",
        "serious complications",
        "grade 3 adverse reactions",
        "grade 4 adverse reactions",
        "grade 5 adverse events",
        "adverse events leading to discontinuation",
        "adverse reactions leading to discontinuation of treatment",
        "treatment-related deaths",
        "treatment-related mortality",
        "dropout rate for toxicity",
        "infections",
        "sepsis",
        "influenza like illness",
        "bleeding",
        "haemorrhage",
        "brain haemorrhage",
        "brain/gastrointestinal bleeding",
        "haemorrhagic events",
        "gastrointestinal perforation",
        "wound healing complications",
        "intraoperative complications",
        "postoperative softening",
        "gallbladder abscess",
        "portal vein thrombosis as a contraindication",
        "tumour seeding",
        "side-effects (biopsy-related)",
        "hand-foot syndrome",
        "hand-foot skin reaction",
        "hand feeding reactions",
        "palmar rash",
        "skin rash",
        "rash",
        "dermatological toxicities",
        "desquamation",
        "skin desquamation",
        "dry skin",
        "erythema",
        "pruritus",
        "pruritus (itching)",
        "alopecia",
        "acne",
        "dermatitis exfoliative",
        "hyperkeratosis",
        "keratoacanthoma",
        "squamous cell cancer of the skin",
        "hypertension",
        "grade 3-4 hypertension",
        "cardiac ischaemia",
        "myocardial ischaemia",
        "cardiac infarction",
        "myocardial infarction",
        "congestive heart failure",
        "cerebral vascular accident",
        "cardiovascular arrest",
        "arterial thromboembolic events",
        "renal adverse events",
        "renal failure",
        "proteinuria",
        "grade 3-4 proteinuria",
        "dysphonia",
        "ascites",
        "hepatic impairment",
        "hepatic insufficiency",
        "hepatic encephalopathy",
        "liver failure",
        "liver disorders",
        "marked impairment of hepatic function",
        "liver and biliary damages",
        "increased aspartate aminotransferase",
        "grade 3-4 increased aspartate aminotransferase",
        "increased alanine aminotransferase",
        "grade 3-4 increased alanine aminotransferase",
        "increased serum bilirubin",
        "grade 3-4 increased serum bilirubin",
        "transient increase in transaminases",
        "jaundice",
        "abdominal swelling",
        "abdominal pain",
        "grade 3-4 abdominal pain",
        "pain",
        "pain (EORTC QLQ-HCC18)",
        "back pain",
        "limb pain",
        "joint pain",
        "arthralgia",
        "myalgia",
        "muscle spasms",
        "fatigue",
        "grade 3-4 fatigue",
        "fatigue (EORTC QLQ-HCC18)",
        "asthenia",
        "grade 3-4 asthenia",
        "decreased appetite",
        "grade 3-4 decreased appetite",
        "loss of appetite",
        "weight loss",
        "decreased weight",
        "nausea",
        "grade 3-4 nausea",
        "vomiting",
        "constipation",
        "diarrhoea",
        "diarrhea",
        "grade 3-4 diarrhoea",
        "dyspepsia",
        "dysphagia",
        "stomatitis",
        "gastro oesophageal reflux disease",
        "mucosal inflammation",
        "anorexia",
        "nutrition (as a symptom domain)",
        "increased amylase",
        "increased lipase",
        "folliculitis",
        "leukopenia",
        "lymphopenia",
        "neutropenia",
        "anaemia",
        "thrombocytopenia",
        "grade 3-4 thrombocytopenia",
        "epilepsy",
        "infusion reaction",
        "grade 3-4 infusion reaction",
        "grade 3-4 fever",
        "fever",
        "fever (EORTC QLQ-HCC18)",
        "cough",
        "dyspnoea",
        "pleural effusion",
        "respiratory failure",
        "headache",
        "headache (as a symptom domain)",
        "depression",
        "peripheral sensory neuropathy",
        "neurotoxicity",
        "dysgeusia",
        "tinnitus",
        "flushing",
        "rhinorrhoea",
        "hypothyroidism",
        "hyperthyroidism",
        "diabetes mellitus",
        "hypocalcaemia",
        "hypokalaemia",
        "hyponatraemia",
        "hypophosphataemia",
        "hypoglycaemia",
        "secondary cancer",
        "increased carcinogenicity",
        "erythema",
        "infusion reaction",
        "serious adverse events",
        "serious adverse reactions (grade 3/4)"
      ],
      "serious_events": [
        "serious adverse events",
        "serious adverse reactions (grade 3/4)",
        "serious complications",
        "treatment-related deaths",
        "treatment-related mortality",
        "grade 5 adverse events"
      ],
      "discontinuations": [
        "adverse events leading to discontinuation",
        "adverse reactions leading to discontinuation of treatment",
        "dropout rate for toxicity"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-HCC18",
        "EORTC QLQ-LC13",
        "EQ-5D",
        "EQ-5D-3L",
        "EQ-5D-5L",
        "EQ-5D VAS",
        "EQ-5D visual analogue scale",
        "EQ-5D health utility index (HUI)",
        "EQ VAS (Euro QoL visual analogue scale)",
        "European Quality of Life – 5 Dimensions Visual Analogue Scale (EQ-5D VAS)",
        "FACT-G (Functional Assessment of Cancer Therapy – General)",
        "FACT-G",
        "FACT-Hepatobiliary (FACT-Hep)",
        "FACT-Hep",
        "SF-36",
        "visual analogue scale",
        "FHSI-8 questionnaire",
        "quality of life measured with a validated and reliable instrument"
      ],
      "functional_status": [
        "Eastern Cooperative Oncology Group Performance Status (ECOG PS)",
        "role functioning (as a symptom domain)",
        "cognitive functioning (EORTC QLQ-C30)",
        "concentration difficulties",
        "nutritional status"
      ],
      "symptom_measures": [
        "pain (EORTC QLQ-HCC18)",
        "jaundice (EORTC QLQ-HCC18)",
        "fever (EORTC QLQ-HCC18)",
        "abdominal swelling (EORTC QLQ-HCC18)",
        "fatigue (EORTC QLQ-HCC18)",
        "nutrition (as a symptom domain)",
        "body image (as a symptom domain)",
        "emotional impact",
        "physical needs",
        "psychological needs",
        "social needs",
        "existential needs"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
        "cost-effectiveness analysis",
        "cost per quality-adjusted life year (QALY)",
        "cost-benefit analysis"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)",
        "quality of life weights (EQ-5D-3L-converted weights with Dolan tariff)",
        "state-specific quality-of-life weights"
      ],
      "resource_utilization": [
        "length of hospital stay",
        "days of missed work",
        "resource use",
        "number needed to treat (NNT)",
        "number needed to harm (NNH)"
      ]
    },
    "other": {
      "exploratory_endpoints": [
        "hazard ratio (HR)",
        "mean difference (MD)",
        "relative risk (RR)",
        "risk difference (RD)",
        "prognosis (BCLC staging system)",
        "prognosis",
        "therapeutic efficacy",
        "early detection of recurrences",
        "progression grading",
        "reassessment in progression classification",
        "bridging therapy success",
        "effectiveness of ablation (magnetic resonance imaging)",
        "effectiveness of ablation (multiphase computed tomography)",
        "effectiveness of ablation (not ultrasonography)",
        "completeness of ablation (multiphase computed tomography with contrast)",
        "completeness of ablation (magnetic resonance imaging with contrast)",
        "histological and prognostic parameters (microscopic detection)",
        "immunohistochemical confirmation of hepatocytic origin",
        "genetic diagnosis (identification of subtypes)",
        "panels of immunohistochemistry markers",
        "genetic tests for metabolic diseases",
        "specific subtypes of tumours",
        "diagnosis (multiphasic CT, MRI, CT and MRI Liver Imaging Reporting and Data System (LI-RADS) v2018, contrast-enhanced ultrasound)",
        "pathological examination"
      ],
      "biomarkers": [
        "laboratory haematological testing",
        "laboratory biochemical testing",
        "urinalysis",
        "vital signs",
        "plasma pharmacokinetics parameters",
        "pharmacokinetic parameters",
        "electrocardiography",
        "liver function (Child-Pugh scale)",
        "liver function",
        "tumour spread (TNM system)",
        "Barcelona Clinic Liver Cancer (BCLC) staging system"
      ]
    }
  }
}